INARI MEDICAL, INC.

(NARI)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
84.69 USD   +4.43%
08/04INSIDER SELL : Inari Medical
MT
08/04INARI MEDICAL : Profile August 2022
PU
08/04INARI MEDICAL : Presentation August 2022
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
79.39(c) 80.93(c) 81.68(c) 81.1(c) 84.69(c) Last
416 922 443 263 729 873 1 325 510 885 356 Volume
+2.33% +1.94% +0.93% -0.71% +4.43% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 368 M - -
Net income 2022 -38,2 M - -
Net cash position 2022 315 M - -
P/E ratio 2022 -116x
Yield 2022 -
Sales 2023 442 M - -
Net income 2023 -11,3 M - -
Net cash position 2023 309 M - -
P/E ratio 2023 -407x
Yield 2023 -
Capitalization 4 522 M 4 522 M -
EV / Sales 2022 11,4x
EV / Sales 2023 9,52x
Nbr of Employees 800
Free-Float 84,5%
More Financials
Company
Inari Medical, Inc. is a medical device company. The Company operates through the development and commercialization of invasive mechanical thrombectomy devices to treat thromboembolism in the venous system. Its product offerings consist of two minimally invasive, catheter-based mechanical thrombectomy systems, which are for venous system and the treatment of the two distinct manifestations of venous thromboembolism... 
More about the company
Ratings of Inari Medical, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about INARI MEDICAL, INC.
08/04INSIDER SELL : Inari Medical
MT
08/04INARI MEDICAL : Profile August 2022
PU
08/04INARI MEDICAL : Presentation August 2022
PU
08/04Inari Medical Promotes COO Drew Hykes to CEO
MT
08/03INARI MEDICAL : Announces Leadership Succession Plan - Form 8-K
PU
08/03INARI MEDICAL, INC. : Change in Directors or Principal Officers, Other Events, Financial S..
AQ
08/03INSIDER SELL : Inari Medical
MT
08/03TRANSCRIPT : Inari Medical, Inc., Q2 2022 Earnings Call, Aug 03, 2022
CI
08/03INARI MEDICAL : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/03INARI MEDICAL, INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
08/03Inari Medical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ende..
CI
08/03Earnings Flash (NARI) INARI MEDICAL Reports Q2 Revenue $92.7M
MT
08/03Inari Medical Reports Second Quarter 2022 Financial Results
AQ
08/03Inari Medical Announces Leadership Succession Plan
AQ
08/03Inari Medical, Inc. Appoints Drew Hykes to Board of Director
CI
More news
News in other languages on INARI MEDICAL, INC.
08/04Inari Medical promeut le COO Drew Hykes au poste de PDG
08/03VENTE D'INITIÉS : Inari Medical
08/03Inari Medical, Inc. annonce ses résultats pour le deuxième trimestre et le semestre clo..
08/03Earnings Flash (NARI) INARI MEDICAL annonce un chiffre d'affaires de 92,7 millions de d..
08/03Inari Medical, Inc. nomme Drew Hykes au conseil d'administration
More news
Analyst Recommendations on INARI MEDICAL, INC.
More recommendations
Chart INARI MEDICAL, INC.
Duration : Period :
Inari Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INARI MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 84,69 $
Average target price 102,50 $
Spread / Average Target 21,0%
EPS Revisions
Managers and Directors
William H. Hoffman President, Chief Executive Officer & Director
Mitchell C. Hill Chief Financial Officer
Don B. Milder Chairman
Thomas Tu Chief Medical Officer
Tara Dunn VP-Clinical Affairs & Market Development
Sector and Competitors
1st jan.Capi. (M$)
INARI MEDICAL, INC.-7.21%4 522
MASIMO CORPORATION-47.59%8 518
SHOCKWAVE MEDICAL, INC.25.13%7 987
NOVOCURE LIMITED0.72%7 920
PENUMBRA, INC.-41.94%6 321
GETINGE AB-44.19%5 869